Pre-Made Efavaleukin Alfa Biosimilar, Fusion Protein targeting IL2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-2/TCGF/lymphokine for drug discovery and mechanism of action (MOA) research

Pre-Made Efavaleukin Alfa Biosimilar, Fusion Protein targeting IL2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-2/TCGF/lymphokine is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efavaleukin alfa contains Immunoglobulin g1 (fc domain-containing fragment) fusion protein with peptide (synthetic linker) fusion protein with interleukin 2 (synthetic human mutein), dimer. Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE were treated using Efavaleukin alfa.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-811-1mg	1mg	3090
GMP-Bios-INN-811-10mg	10mg	Inquiry
GMP-Bios-INN-811-100mg	100mg	Inquiry
GMP-Bios-INN-811-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Efavaleukin Alfa Biosimilar, Fusion Protein targeting IL2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-2/TCGF/lymphokine
INN Name	Efavaleukin Alfa
Target	IL2
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - IGHG1 Fc (Fragment constant) - [IL2 (interleukin 2, IL- 2)]2
VD LC	Fusion - IGHG1 Fc (Fragment constant) - [IL2 (interleukin 2, IL- 2)]2
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Amgen (Thousand Oaks CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0